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We have investigated the role of erythroid transcription factors mRNA expression in patients with acute myeloid
leukemia (AML) in the context of cytogenetic and other prognostic molecular markers, such as FMS-like Tyrosine
Kinase 3 (FLT3), Nucleophosmin 1 (NPM1), and CCAAT/enhance-binding protein α (CEBPA) mutations. Further
validation of Erythroid Krüppel-like Factor (EKLF) mRNA expression as a prognostic factor was assessed.
We evaluated GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), EKLF and Myeloproliferative
Leukemia virus oncogen homology (cMPL) gene mRNA expression in the bone marrow of 65 AML patients at
diagnosis, and assessed any correlation with NPM1, FLT3 and CEBPA mutations. EKLF-positive AML was associated
with lower WBC in peripheral blood (P = 0.049), a higher percentage of erythroblasts in bone marrow (p = 0.057),
and secondary AMLs (P = 0.036). High expression levels of EKLF showed a trend to association with T-cell antigen
expression, such as CD7 (P = 0.057). Patients expressing EKLF had longer Overall Survival (OS) and Event Free
Survival (EFS) than those patients not expressing EKLF (median OS was 35.61 months and 19.31 months,
respectively, P = 0.0241; median EFS was 19.80 months and 8.03 months, respectively, P = 0.0140). No correlation of
GATA1, GATA2, EKLF and cMPL levels was observed with FLT-3 or NPM1 mutation status. Four of four CEBPA
mutated AMLs were EKLF positive versus 10 of 29 CEBPA wild-type AMLs; three of the CEBPA mutated, EKLF-
positive AMLs were also GATA2 positive. There were no cases of CEBPA mutations in the EKLF-negative AML group.
In conclusion, we have validated EKLF mRNA expression as an independent predictor of outcome in AML, and its
expression is not associated with FLT3-ITD and NPM1 mutations. EKLF mRNA expression in AML patients may
correlate with dysregulated CEBPA.
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mutationsBackground
Functional disturbance of transcription factors involved
in normal erythroid and megakaryocytic development,
such as GATA binding protein 1 (GATA1), GATA bind-
ing protein 2 (GATA2), Erythroid Krüppel-like Factor
(EKLF) and Myeloproliferative Leukemia virus oncogen
homology (c-MPL), is frequent in acute myeloid
leukemia (AML), but the role of these disturbances in
AML subtypes is unknown.
EKLF is a transcription factor that plays a critical role
in erythroid cell differentiation. It activates adult
hemoglobin through a highly conserved CACCC motif,* Correspondence: rayaladiaz@hematologia12octubre.com
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reproduction in any medium, provided the orknown to mutate in human beta-thalassemias [1], and
restricts megakaryocytic differentiation to the benefit of
erythroid differentiation [2]. The EKLF gene dosage is
crucial for regulating the surface phenotype and molecu-
lar identity of maturing primitive erythroid cells [3].
GATA1 expression is particularly important for proper
differentiation and maturation of erythroid cells and
megakaryocytes [4]. GATA1-null cells stall at the pro-
erythroblast stage, after which they readily undergo
apoptosis [5]. GATA2, another member of the GATA
family, plays essential roles in hematopoietic stem cell
and progenitor cell compartments during normal
hematopoiesis. GATA2 also contributes to cell cycle pro-
gression, and the maintenance of megakaryocyte identity
in GATA1-deficient cells. Moreover, overexpression of
GATA2 facilitates aberrant megakaryopoiesis [6]. cMPL
is an active player in early hematopoiesis [7] from thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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through to the direct regulation of the expression of
transcription factors or genes important in the self-
renewal, proliferation and apoptosis of hematopoietic
stem cells [8]. Transcription factor acute myeloid
leukemia 1 (AML1)/Runt-related transcription factor 1
(Runx1) regulates the c-MPL promoter, both positively
and negatively, by changing the binding partner accord-
ing to cell type [9].
AML is characterized by heterogeneity and, despite re-
cent progress, still remains a highly fatal disease. The
most important outcome predictor in AML is cytogen-
etic findings. However, treatment stratification is still not
ideal, particularly in the case of cytogenetically normal
AML (CN-AML, 40%-50% of cases). In CN-AML, mo-
lecular markers such as aberrations in the nucleophos-
min (NPM1) and FMS-related tyrosine kinase 3 (FLT3)
genes have been shown to be clinically relevant. NPM1
mutation is classified as a primary genetic lesion (so-
called class II mutation) that impairs hematopoietic dif-
ferentiation [10]. The tyrosine kinase receptor, FLT3, is
expressed in early hematopoietic progenitor cells and
mediates important functions for proliferation and sur-
vival. Mutations in the FLT3 gene are found in many
AML subtypes and are considered class I mutations con-
ferring a proliferation and/or survival advantage of the
leukemic blasts [10]. In the presence of the FLT3 muta-
tion, expression and function of several myeloid tran-
scription factors are significantly repressed, in contrast
to the induction caused by the activation of wild-type
FLT3. These results indicate that FLT3 mutations induce
aberrant receptor function which influence, not only
proliferation and survival, but also the myeloid differen-
tiation program [11].
The transcription factor CCAAT enhancer binding
protein alpha (CEBPA) [12] is crucial for normal devel-
opment of granulocytes and there is evidence that
impaired CEBPA function contributes directly to the de-
velopment of AML [13]. Various mechanisms have been
identified as to how CEBPA function is dysregulated in
patients with acute myeloid leukemia (AML). Mutations
either in combination on separate alleles, or as sole
mutations, or through promoter methylation by DNA
methyltransferase, have been described [14]. In the ab-
sence of a co-existent FLT3-ITD (internal tandem dupli-
cation), a CEBPA mutation confers a significantly better
prognosis in patients with CN-AML [15], with approxi-
mately 60% long-term survival, particularly if a “double”
(bi-allelic) mutation is found [16].
We previously reported EKLF to be a favorable prog-
nostic marker in AML. Higher EKLF expression was
found in secondary AMLs versus primary AMLs, and
patients expressing EKLF had longer overall survival
(OS) and event-free survival (EFS), than those withoutEKLF [17]. However, no relationship between the dysre-
gulation of erythroid transcription factors in AML and
the presence of NPM1 and FLT3 mutations has been
reported. Nevertheless, mutations of the CEBPA gene
are associated with the upregulation of several genes
involved in erythroid differentiation [18].
As CEBPA mutations are associated with the upregula-
tion of genes involved in erythroid differentiation in a
subtype of AML with higher hemoglobin levels and bet-
ter outcome, we speculate that the AML subtype defined
by EKLF expression may be generated via CEBPA silen-
cing. We aim to validate EKLF expression as a favorable
prognostic predictor in the context of other molecular
markers in cytogenetically normal (CN) acute myeloid
leukemia (AML).
Results
GATA1, GATA2, EKLF, and cMPL mRNA expression
GATA1 expression was detected in 35 cases and the
average, median (range) of expression was 3.98, 0.0569
(0.006-176). GATA2 expression was detected in 40 cases
and the average, median (range) of expression was
849.74, 0.2724 (0.003-39913.4). EKLF expression was
detected in 35 cases and the average, median (range) of
expression was 15.49, 0.1770 (0.0004-772.0). cMPL ex-
pression was detected in 46 cases and the average, me-
dian (range) of expression was 10.25, 0.8391 (0.01-132.9).
EKLF levels in the AML samples had significant posi-
tive correlations with levels of GATA1 (Rho 0.298,
P = 0.008); GATA2 (Rho 0.263, P = 0.017), and cMPL
(Rho 0.230, P = 0.033). There was a tendency to a posi-
tive correlation between levels of GATA1 and GATA2
(Rho 0.188, P = 0.067).
Characteristics of AML patients expressing GATA1,
GATA2, EKLF, and cMPL
The characteristics of GATA1-positive AML patients
were: male (P = 0.011) and older age (P = 0.011). They
showed frequent co-expression of EKLF (24 of 35
GATA1 positives versus 11 of 30 GATA1 negatives,
P = 0.010), and median EKLF expression was higher in
this subtype than GATA1-negative AML patients (27.4
versus 1.6, P = 0.019) (Table 1). GATA1 expression was
significantly different among FAB classes (P= 0.043)
(Figure 1a).
The characteristics of GATA2-positive AML patients
were: no alterations in chromosome 7 (P = 0.007), chro-
mosome 11 (P = 0.011) or chromosome 5 (P = 0.065).
They showed frequent co-expression of EKLF (27 of 40
GATA2 positives versus 8 of 25 GATA2 negatives,
P = 0.005) and the expression median of EKLF was
higher (20.4 versus 1.6, P = 0.017) (Table 1). GATA2 ex-
pression was found to be significantly different among
FAB classes (P = 0.007)(Figure 1b).
Table 1 Comparison of clinical and biological characteristics between acute myeloid leukemia (AML) patients, with or
without GATA-1 and GATA-2 expression
Gata-1 positive Gata-1 negative P Gata-2 positive Gata-2 negative P
Gender of patients (male/female) 25/10 12/18 0.011 25/15 12/13 0.251
Age/years (median) 57.3 42.2 0.011 52.7 44.7 0.187
Status Performance/ECOG 6/11/12/6/0 11/7/8/3/1 0.308 10/13/11/5/1 7/5/9/4/0 0.728
WBC count, x109/L(median) 34.98 34.34 0.965 30.6 41.1 0.473
Hemoglobin, g/dL (median) 9.3 9.8 0.303 9.8 9.3 0.168
platelet count, x109/L (median) 103.4 75.4 0.219 102.2 73.6 0.217
Percentage of Blasts in PB (median) 36.7 49 0.153 42.8 41.6 0.885
M2 vs. non-M2 FAB 5/29 6/24 0.575 6/33 5/20 0.633
M3 vs.non-M3 FAB 4/30 5/24 0.536 6/33 3/21 0.751
WHO Type 8/9/2/14 6/7/1/15 0.885 9/10/2/17 5/6/1/2 0.980
Primary/Secondary LMA 25/10 26/4 0.136 31/9 20/5 0.811
Cytogenetic (MRC) 8/16/7 7/15/5 0.924 10/20/5 5/11/7 0.329
Cr 7 Alterations (yes/no) 3/28 4/24 0.585 1/35 6/17 0.007
Cr 5 Alterations (yes/no) 2/29 5/23 0.176 2/34 5/18 0.061
Cr 11 Alterations (yes/no) 5/26 6/22 0.602 3/33 8/15 0.011
CD34 Blasts (yes/no) 19/16 14/15 0.820 20/19 13/12 0.955
CD117 Blasts (yes/no) 25/10 16/13 0.177 25/14 16/9 0.993
CD15 Blasts (yes/no) 16/15 15/13 0.880 17/19 14/9 0.306
CD11B Blasts (yes/no) 10/21 8/18 0.945 12/24 6/15 0.709
CD11C Blasts (yes/no) 8/1 7/3 0.313 5/7 10/2 0.539
CD 133 Blasts (yes/no) 11/16 9/11 0.770 12/17 8/10 0.836
CD 123 Blasts (yes/no) 6/14 6/9 0.537 4/18 8/5 0.009
HLA DR + Blasts (yes/no) 21/7 13/14 0.040 23/11 11/10 0.258
CD56 Blast (yes/no) 5/30 6/24 0.540 6/34 5/20 0.601
T-cell markers Blast (yes/no) 5/13 4/18 0.470 5/15 4/16 0.705
Erythroblasts BM 1/8/12 1/12/9 0.359 1/10/11 1/10/10 0.335
Gata-1 Expression (yes/no) 25/15 10/15 0.077
Gata-2 Expression (yes/no) 25/15 10/15 0.077
EKLF Expression (yes/no) 24/11 11/19 0/010 27/13 8/17 0.005
cMPL Expression (yes/no) 26/9 20/10 0.501 31/9 15/10 0.131
Gata-1 (Median Expression)* 6.37 0.14 0.090
Gata-2 (Median Expression) 253.1 1545.85 0.182
EKLF (Median Expression) 27.4 1.6 0.019 20.4 7.6 0.017
cMPL (Median Expression)* 9.2 11.5 0.780 11.97 7.50 0.181
Mutated NPM1 (yes/no) 4/20 5/15 0.495 6/22 3/13 0.832
Mutated FLT3 (yes/no) 2/22 7/13 0.029 6/22 3/13 0.832
PS, Performance Status. WBC, white blood cell. FAB indicates French American British classification [19] and WHO indicates World Health Organization
classification [20]. MRC, cytogenetic classification of Medical Research Cancer [21]. GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid
Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL). * All expression ratios are given as 100x target gene/GUS.
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were: lower WBC in peripheral blood (median 21.05 ver-
sus 51.15, P = 0.049), a higher percentage of erythroblasts
in bone marrow (median P = 0.057), and higher fre-
quency of secondary AMLs (11 of 35 EKLF positives ver-
sus 3 of 30 EKLF negatives, P = 0.036). They showed
frequent co-expression of GATA1 (24 of 35 EKLF posi-
tives versus 11 of 30 EKLF negatives, P = 0.010), andGATA2 (27 of 35 EKLF positives versus 13 of 30 nega-
tives, P = 0.005), and the expression median of GATA1
was higher (7.28 versus 0.12, P = 0.038). A tendency to
co-express cMPL (28 of 35 EKLF positives versus 18 of
30 EKLF negatives, P = 0.077) was observed (Table 2).
No differences were found between FAB groups (Fig-
ure 1c). AML patients with high expression levels of
EKLF tended to express T-cell markers such as CD7
a c
b d
Figure 1 Boxplot of GATA1 (1a), GATA2 (1b), EKLF (1c), and cMPL (1d) mRNA expression of in different AML subtypes. EKLF expression
was found to have no significant difference among French American British (FAB) classes. GATA-1, GATA-2 and CMPL expression were
significantly different among FAB classes (P = 0.043; P = 0.007 and P = 0.025, respectively). GATA binding protein 1 (GATA1), GATA binding protein
2 (GATA2), Erythroid Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL).
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expression EKLF, P = 0.057).
The characteristics of cMPL-positive AML patients
were: lower WBC in peripheral blood (median 22.4 ver-
sus 63.7, P = 0.006); a lower percentage of blasts in per-
ipheral blood (median 37.2 versus 53.4, P = 0.077). They
showed a tendency to co-express EKLF, but not GATA1
or GATA2 (Table 2). cMPL expression was found to be
significantly different among FAB classes (P = 0.016);
cMPL levels were higher in FAB type M5 (P = 0.025)
(Figure 1d).
In the multivariable analysis GATA1 expression
was associated with EKLF expression (no/yes) (HR
4.69; 95%CI 1.48-14.82, P = 0.008), and patient age(continuous variable) (HR 1.04; 95%CI 1.01-1.07,
P = 0.005). GATA2 expression was associated with
EKLF expression (no/yes) (HR 13.32; 95%CI 2.80-63.35,
P = 0.001), patient age (continuous variable) (HR 1.04;
95%CI 1.001-1.079, P = 0.04), and AML without
chromosome 7 alterations (no/yes) (HR 0.02; 95% CI
0.001-0.25, P = 0.002). EKLF expression was associated
with secondary AML (primary/secondary) (HR 10.71;
95%CI 1.54-74.49, P = 0.02), GATA2 expression (no/yes)
(HR 5.45; 95% CI 1.5-19.68, P = 0.009), and cMPL ex-
pression (no/yes) (HR 5.16; 95%CI 1.51-23.08, P = 0.03).
cMPL expression was associated with low WBC in
peripheral blood (continuous variable) (HR 0.99; 95%CI
0.97-0.99, P = 0.04).
Table 2 Comparison of clinical and biological characteristics between acute myeloid leukemia (AML) patients, with or
without EKLF and C-MPL expression
Eklf positive Eklf negative P cMpl positive cMpl negative p
Gender of patients (male/female) 22/13 15/15 0.297 25/21 12/7 0.514
Age/years (median) 46.0 50.6 0.463 46.2 53.8 0.237
Status Performance/ECOG 8/13/10/4/0 9/5/10/54 0.359 14/13/13/5/1 3/5/7/4/0 0.581
WBC count,x109/L (median) 21.05 51.15 0.049 22.4 63.7 0.006
Hemoglobin, g/dL (median) 9.5 9.5 0.920 9.6 9.2 0.396
Platelet count, x109(median) 107.0 71.1 0.114 84.3 106.1 0.388
Percentage of Blasts in PB (median) 38.3 47.5 0.290 37.2 53.4 0.077
M2 vs.non-M2 FAB 4/30 7/23 0.221 7/39 4/14 0.504
M3 vs.non-M3 FAB 7/28 2/26 0.147 8/37 1/17 0.210
M5 vs.non-M5 FAB 4/30 8/22 0.127 10/36 2/16 0.327
WHO Type 9/10/3/12 11/12/1/20 0.140 11/12/1/20 3/4/2/9 0.451
Primary/Secondary LMA 24/11 27/3 0.036 37/9 14/5 0.547
Cytogenetic (MRC) 10/16/6 5/15/6 0.580 11/22/9 4/9/3 0.961
Cr 7 Alterations (yes/no) 5/27 2/25 0.331 4/39 3/13 0.318
Cr 5 Alterations (yes/no) 2/30 5/22 0.147 5/38 2/14 0.927
Cr 11 Alterations (yes/no) 6/26 5/22 0.982 7/36 4/12 0.444
CD34 Blasts (yes/no) 19/16 14/15 0.632 24/21 9/10 0.663
CD117 Blasts (yes/no) 22/13 19/10 0.825 29/16 12/7 0.922
CD15 Blats (yes/no) 12/19 19/9 0.025 19/22 12/6 0.150
CD11B Blasts (yes/no) 5/25 13/14 0.011 13/28 5/11 0.973
CD11C BLasts (yes/no) 5/0 10/4 0.179 10/2 5/2 0.539
CD133 BLasts (yes/no) 10/18 10/9 0.250 16/19 4/8 0.454
CD123 Blasts (yes/no) 5/16 7/7 0.110 6/18 6/5 0.087
HLA DR+ BLasts (yes/no) 19/9 15/12 0.348 26/14 8/7 0.428
CD56 Blasts (yes/no) 6/29 5/25 0.959 7/39 4/15 0.568
T-cell markers Blasts (yes/no) 5/11 4/20 0.279 3/23 6/8 0.024
Erythroblasts BM 2/6/11 0/14/10 0.057` 1/12/17 1/8/4/3 0.460
Gata-1 Expression (yes/no) 24/11 11/19 0.010 26/20 9/10 0.501
Gata-2 Expression (yes/no) 27/8 13/17 0.005 31/15 9/10 0.131
EKLF Expression (yes/no) 28/18 7/12 0.077
cMPL Expression (yes/no) 28/7 18/12 0.007
Gat-1 (Median Expression)* 7.28 0.12 0.038 5.56 0.12 0.761
Gat-2 (Median Expression)* 1178.01 466.75 0.096 1009.84 462.12 0.552
EKLF (Median Expression)* 19.54 113.68 0.096
cMPL(Median Expression)* 10.9 9.4 0.174
Mutated NPM1 (yes/no) 3/20 6/15 0.202 4/25 5/10 0.128
Mutated FLT3 (yes/no) 4/19 5/16 0.598 4/25 5/10 0.128
PS, Performance Status. WBC, white blood cell. FAB indicates French American British classification [19] and WHO indicates World Health Organization
classification [20]. MRC, cytogenetic classification of Medical Research Cancer [21]. GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid
Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL). * All expression ratios are given as 100x target gene/GUS.
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GATA2, EKLF and cMPL mRNA expression
NPM1 exon 12 mutations were detected in 20.5% of the
studied AML samples, and FLT3 mutations were
detected in 18.2%.NPM1 mutations were associated with a high per-
centage of blasts in peripheral blood (79.7 versus 33.1,
P< 0.001), a high percentage of bone marrow blasts
(91.2 versus 63.5, P< 0.001) and de novo AML (100% de
novo AML with NPM1 mutations versus 71.43% de novo
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ation with GATA1, GATA2, EKLF, and cMPL expression
were shown. No correlation was observed between
GATA1, GATA2, EKLF and cMPL levels and NPM1 mu-
tation status (Table 3).Table 3 Comparison of clinical and biological characteristics b
without NPM1 and FLT3-ITD mutations
Mutated NPM1 WT NPM1
Gender of patients (male/female) 7/2 19/16
Age/years (median) 56.0 50.6
Status Performance/ECOG 3/3/1/2 9/7/15/4
WBC count,x109/L (median) 109.60 17.14
Hemoglobin, g/dL (median) 9.59 9.35
Platelet, count, x109/L (median) 58.0 94.4
Percentage of Blasts in PB (median) 79.7 33.1
Percentage of Blasts in BM (median) 91.2 63.5
M2 vs. non-M2 FAB 1/8 8/27
M3 vs. non-M3 FAB 3/6 4/31
M5 vs. non-M5 FAB 3/6 4/31
FAB Type 1/1/1/0/3/0/0/02/1 3/8/4/1/4/2/1/9
WHO Type 1/0/0/8 7/11/12/12
Primary/Secondary LMA 9/0 25/10
Cytogenetic (MRC) 1/7/1 8/18/4
Cr 7 Alterations (yes/no) 0/9 4/26
Cr 5 Alterations (yes/no) 1/8 2/28
Cr 11 Alterations (yes/no) 2/7 5/25
CD34 Blasts (yes/no) 2/7 20/15
CD117 Blasts (yes/no) 7/2 22/13
CD15 Blasts (yes/no) 7/2 12/20
CD11B Blasts (yes/no) 4/5 5/25
CD11C Blasts (yes/no) 2/1 6/2
CD133 Blasts (yes/no) 2/3 12/16
CD123 Blasts (yes/no) 2/3 5/18
HLA DR+ BLasts (yes/no) 3/6 19/18
CD56 Blasts (yes/no) 3/6 19/18
T-cell markers BLast (yes/no) 1/6 4/13
Erythroblasts BM 0/4/1 2/8/12
Gata-1 Expression (yes/no) 4/5 17/18
Gata-2 Expression (yes/no) 5/4 17/18
EKLF Expression (yes/no) 3/6 18/17
cMPL Expression (yes/no) 3/6 17/18
Gata-1 (Median Expression)* 0.127 5.187
Gata-2 (Median Expression)* 568.23 1273.38
EKLF (Median Expression)* 0.0345 23.62
cMPL (Median Expression)* 3.61 7.01
Nucleophosmin (NPM1) and FMS-related tyrosine kinase 3 (FLT3) genes. PS, Perform
classification [19] and WHO indicates World Health Organization classification [20].
protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid Krüppel-like Factor (E
expression ratios are given as 100x target gene/GUS.FLT3 mutations were associated with a high percent-
age of blasts in peripheral blood (66.38 versus 37.78,
P = 0.013). FLT3 AML showed a tendency towards asso-
ciation with high WBC (P = 0.051) and de novo AML
(P = 0.090). FLT3 mutations were more frequent in AMLetween acute myeloid leukemia (AML) patients, with or
p ITD FLT3 WT FLT3 p
0.201 5/3 21/5 0.828
0.560 52.0 52.3 0.975
0.347 2/4/1/1 10/6/15/5 0.190
0.001 80.04 26.28 0.051
0.724 9.46 9.39 0.893
0.332 60.87 93.64 0.142
<0.001 66.38 27.78 0.013
<0.001 80.29 66.69 0.132
0.436 3/5 6/30 0.186
0.109 1/7 6/30 0.771
0.109 1/7 6/30 0.771
/0/0 0.053 1/3/0/0/1/0/0/1/1/1/8 3/6/5/1/6/2/1/8/1/0 0.420
0.049 1/2/0/5 7/9/2/15 0.770
0.068 8/0 26/10 0.090
0.579 1/7/0 8/18/5 0.267
0.248 0/8 4/27 0.284
0.661 1/7 2/29 0.567
0.703 2/6 5/25 0.560
0.062 4/5 18/17 0.709
0.400 8/1 21/14 0.103
0.032 6/3 13/19 0.166
0.083 2/7 7/23 0.945
0.782 2/2 6/1 0.201
0.905 2/3 12/16 0.905
0.393 2/2 5/19 0.212
0.408 4/5 18/9 0.236
0.048 4/5 18/9 0.236
0.612 2/6 3/13 0.722
0.312 0/4/3 2/8/10 0.271
0.825 2/6 17/19 0.155
0.709 4/4 18/18 1
0.332 3/5 18/18 0.522
0.413 2/6 18/18 0.199
0.615 0.107 5.051 0.639
0.759 5000.50 268.84 0.375
0.593 2.143 22.5 0.660
0.608 4.258 6.768 0.639
ance Status. WBC, white blood cell. FAB indicates French American British
MRC, cytogenetic classification of Medical Research Cancer [21]. GATA binding
KLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL). * All
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No association with GATA2, EKLF, and cMPL expres-
sion (yes/no) was shown. No correlation was observed
between GATA1, GATA2, EKLF, and cMPL levels and
FLT-3 mutation status (Table 3). Cuplike blast morph-
ology was not associated with FLT3-ITD AMLs, and
only 2 of 9 FLT3-ITD positive AMLs had cuplike blast
morphology, however both patients had high mutation
levels (Figure 2).
CEBPA mutations and their correlations with GATA1,
GATA2, EKLF and cMPL mRNA expression
CEBPA mutations were detected in 4/33 studied cases
(12.12%), only one of which was bi-allelic. Four of four
CEBPA mutated AMLs were EKLF positive, and 10/29
CEBPA wild-type AMLs and three of CEBPA-mutated,
EKLF-positive AMLs were also GATA-2 positive. We
should stress that no case with mutated CEBPA was
found in the EKLF-negative AML group.
EKLF mRNA expression was a strong favorable prognostic
factor for overall survival and remission duration in AML
A prognostic study was performed in 50 patients with
AML non-M3, treated with intensive chemotherapy (14
were new patients and 36 previously reported) [17]. The
patients studied had a high mortality rate and recurrent
leukemia episodes. Univariate analysis found no differ-
ences in OS and EFS between patients with and without
GATA1, GATA2, and cMPL expression. Patients expres-
sing EKLF had longer OS and EFS than those without
EKLF (median OS was 35.61 months and 19.31 months,Figure 2 Morphology of acute myeloid leukemia with cuplike blasts (
[22]). Only two of nine FLT3-ITD AMLs had cuplike blast morphology, howrespectively, P = 0.0241; median EFS was 19.80 months
and 8.03 months, respectively, P = 0.0140) (Figures 3 and
4). Patients overexpressing GATA1, GATA2, and cMPL
showed no differences in OS and EFS. Patients overex-
pressing EKLF had a tendency to longer OS and EFS
(median OS was 36.69 months and 19.31 months, re-
spectively, P = 0.0682; median EFS was 29.05 months
and 8.66 months, respectively, P = 0.0832).
In multivariate analysis considering known prognostic
factors (age, gender, type of leukemia, cytogenetic risk
group, WBC, FLT3/ITD, and NPM1 mutant status),
EKLF expression (yes/no) remained an independent fa-
vorable prognostic factor for EFS (HR 0.4504, 95%CI
0.2115-0.9589, P = 0.038) (Table 4). OS was not corre-
lated with any factor when stepwise multivariate analysis
was performed. Other studied transcription factors had
no influence in OS or EFS in multivariate analysis.
Discussion
We assessed the prognostic significance of mRNA expres-
sion of erythroid transcription factors in the context of
other cytogenetic and molecular markers in AML. The
results demonstrated that GATA1, GATA2, EKLF, and
cMPL were variably expressed in newly diagnosed AML
patients. EKLF expression was a strong favorable prognos-
tic factor for overall survival and remission duration, as
previously reported [17]. We have validated EKLF expres-
sion as an independent predictor of outcome in AML.
We attempted to document the dysregulation of eryth-
roid transcription factors and the presence of NPM1 and
FLT3 mutations in CN-AML. However, the presence ofWright-Giemsax1000) (McCormick SR, Arch Pathol Lab Med 2010



















































































































































Figure 3 Univariate analysis found no differences in overall survival (OS) between patients, with and without GATA-1 (3a), GATA-2
(3b), EKLF (3c) and cMPL (3d) mRNA expression. Patients expressing EKLF had longer OS than those patients not expressing EKLF (median OS
was 35.61 months and 19.31 months, respectively, P = 0.0241). GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid
Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL).
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http://www.cancerci.com/content/12/1/25NPM1 and FLT3 mutations were not associated with cases
expressing GATA1, GATA2, EKLF, and cMPL. ITD-FLT3
was more frequent in the AML group that lacked GATA1
expression. ITD mutations inhibit the expression and
function of transcription factors involved in myeloid dif-
ferentiation [11], and GATA1 in hematopoietic cells
with ITD mutations can also be downregulated. How-
ever, enforced ITD-FLT3 expression in CD34+ cells
from cord blood show enhanced erythropoietic potential
[23]. In our study, FLT3-ITD AML was associated with
de novo AML, and high WBC and blast cell counts in
peripheral blood, as described. Incidentally only two of
eight FLT3-ITD AML cases, both with a high FLT3
mutation burden, presented a cuplike blast morphology
[22]. NPM1 mutated AML was associated with high
WBC and blast cell counts in peripheral blood and
bone marrow, a M5 FAB subtype, negative CD34 blasts,
and positive CD15 and CD11B blasts, as previously
reported [24,25].EKLF or KLF1 is a member of the zinc family of tran-
scription factors able to bind to GC-rich sequences that
are critical regulators of important functions all over the
body. It is involved in hematopoiesis, particularly in
erythropoiesis, and is also expressed in macrophages
[26]. EKLF has surprisingly been associated with tumors
such as cancer in the endometrial epithelial cells, and is
increased by treatment with tamoxifen or oestrogen
[27].
EKLF mRNA expression is correlated with expression
levels of other transcription factors, e.g., GATA1,
GATA2, and cMPL. Nevertheless the biological charac-
teristics associated with the AML groups expressing
GATA1, GATA2, EKLF and cMPL were not completely
concordant. GATA1 mRNA expression was more fre-
quent in elderly patients than in AMLs with EKLF ex-
pression. GATA2 mRNA expression was more frequent
in the group with no abnormalities in Chromosomes 7,
























































































































































Figure 4 Univariate analysis found no differences in event free survival (EFS) between patients, with and without GATA-1 (4a), GATA-2
(4b), EKLF (4c) and cMPL (4d) mRNA expression. Patients expressing EKLF had longer EFS than those patients not expressing EKLF (median
EFS was 19.80 months and 8.03 months, respectively, P = 0.0140). GATA binding protein 1 (GATA1), GATA binding protein 2 (GATA2), Erythroid
Krüppel-like Factor (EKLF) and Mieloproliferative Leukemia virus oncogen homology (c-MPL).
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http://www.cancerci.com/content/12/1/25accord with the EKLF-expressing AML group, with a
low WBC count and FAB M1 or M5 subtypes, but with
no influence on prognosis. The causes of these differ-
ences are not clear although they could be related to
other variables, such as cytogenetic aberrations. Cyto-
genetic subtype is the most important outcome predictor
in AML, but other factors can also play a role. Thus, in
a work recently published on genetic aberrations in the
leukemogenesis of pediatric AML, genes of the HOXB
cluster were overexpressed in all patients with a FLT3-
ITD positive CN-AML, but not in those with a FLT3-
ITD positive and translocation t (15;17)(q21;q22); a
finding in agreement with differences in prognostic rele-
vance between these two subgroups [28]. Le Beau
described the loss of GATA1 and EKLF expression in
secondary therapy related AML (t-AML) with abnormal-
ities of chromosome 7 but not of chromosome 5 (Group
A). On the other hand our patients with similar charac-
teristics showed a loss of GATA1 expression, but con-
served EKLF expression and, as Le Beau described, noneof these patients had FLT3-ITD mutations. The exact
mechanism of dysregulation in these patients remains
elusive [29].
In our study GATA2 mRNA expression was not asso-
ciated with cases with chromosome 7, 5 and 11 abnor-
malities, and AMLs with minimal differentiation (FAB
AML-M0 and CD123 expression). Acute leukaemias are
commonly caused by mutations or cytogenetic aberra-
tions that corrupt the transcriptional circuitry of haem-
atopoietic stem/progenitor cells. Recently, Bonadies
et al. reported that GATA2 expression is downregulated
during the development of AML by abundant GATA
motifs in regions of reduced histone acetylation, suggest-
ing an important role in leukemogenic transcriptional
reprogramming [30]. Other implications of GATA2 are
seen in the neuroblastoma: GATA2, essential for normal
SNS development, is downregulated in aggressive neuro-
blastoma [31].
Association of CEBPA mutations with the upregula-
tion of several genes involved in erythroid differentiation
Table 4 Multivariate analysis of clinical factors affecting
overall survival and event free survival of acute myeloid
leukemia (AML) patients
Variable p Hazard Ratio (CI)
a) OVERALL SURVIVAL
Age (continuous variable) 0.315
Gender (male/female) 0.7822
WBC (continuous variable) 0.9718
Chromosome 5 alterations 0.0535
Gata-1 expression (negative/positive) 0.4750
Gata-1 over-expression (zero-low/high) 0.9489
Gata-2 expression (negative/positive) 0.4750
Gata-2 over-expression (zer0-low/high) 0.3677
Eklf expression (negative/positive) 0.0878
Eklf over-expression (zero-low/high) 0.0772
cMPL epression (negative/positive) 0.8023
cMPL over-expression (zero-low/high) 0.7546
DIT-FLT3 (WT/mutated) 0.283
NPM1 mutations (no/yes) 0.234
Cytogenetic risk (intermediate/good) 0.287
Cytogenetic risk (adverse/good) 0.139
b) EVENT FREE SURVIVAL
Age (continuous variable) 0.6064
Gender (male/female) 0.9844
WBC (continuous variable) 0.757
Chromosome 5 alterations 0.6525
Gata-1 expression (negative/positive) 0.7682
Gata-1 over-expression (zero-low/high) 0.7405
Gata-2 expression (negative/positive) 0.9438
Gata-2 over-expression (zero/low/high) 0.3330
Eklf expression (negative/positive) 0.0385 0.4504 (0.2115-0.9589)
Eklf over expression (zero-low/high) 0.4693
cMPL expression (negative/positive) 0.4099
cMPL over-expression (zero-low/high) 0.8863
DIT-FLT3 (WT/mutated) 0.084
NPM1 mutations (no/yes) 0.120
Cytogenetic risk (intermediate/good) 0.704
Cytogenetic risk (adverse/good) 0.320
In multivariate analysis considering known prognostic factors (age, gender,
type of leukemia, cytogenetic risk group, WBC, FLT3/ITD, and NPM1 mutant
status), EKLF expression (yes/no) remained an independent favorable
prognostic factor for event free survival (EFS) (HR 0.4504, 95%CI 0.2115-
0.9589). Overall survival (OS) was not correlated with any factor when stepwise
multivariate analysis was performed. WBC, white blood cell; MRC, cytogenetic
classification of Medical Research Cancer [21]. GATA binding protein 1
(GATA1), GATA binding protein 2 (GATA2), Erythroid Krüppel-like Factor (EKLF)
and Mieloproliferative Leukemia virus oncogen homology (c-MPL).
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study in CN-AML [32]. CEBPA mutations were asso-
ciated with upregulation of GATA1, and other genesinvolved in erythroid differentiation, such as EKLF. In
contrast, genes involved in myeloid differentiation, in-
cluding RUNX1, SPI1, and ID1 were downregulated
[32]. CEBPA mutations and NPM1 mutations are mutu-
ally exclusive [15,16] and our EKLF-positive AML
group was not associated with NPM1 mutated cases.
Silencing CEBPA production, an important event in
leukemogenesis, could follow the mutation of CEBPA
and/or promoter methylation by DNA methyltrans-
ferases [13,14]. In our study, EKLF-positive AMLs were
secondary leukemias with a low WBC count, CD15,
CD11B and T-cell marker expression (such as CD7) in
the blast cells, and high erythroblast percentage in the
bone marrow. These AML subtypes showed a favorable
prognosis.
AMLs with CEBPA mutations show many characteris-
tics also found in the EKLF-positive AML group, such as
a high percentage of erythroblasts and favorable out-
come. Although the study population was small, we
found that all four cases with CEBPA mutations showed
EKLF expression, and no case with mutated CEBPA was
found in the EKLF-negative AML group. These results
support the theory that EKLF expression could be pro-
duced through CEBPA dysregulation, either due to
mutations or methylation. In this particular group of
CEBPA-mutated AMLs, validating EKLF expression as
an independent prognostic factor would require a
greater number of cases.
Conclusion
We have further validated EKLF mRNA expression as
an independent predictor of outcome in AML not asso-
ciated with FLT3-ITD and NPM1 mutations. Although
additional studies are needed, EKLF expression in AML
patients may be related to dysregulated CEBPA. Down-
regulation of GATA1 expression was found in FLT3-ITD
AML or AML with cytogenetic abnormalities of
chromosome 7, and GATA-2 downregulation was found
in AML with chromosome 5, 7 and 11 abnormalities
and undifferentiated AML, but the exact underlying
mechanisms remain unknown. It remains to be proved
whether transcription factor expression, including EKLF,
GATA1 and GATA2, could accurately predict some
cytogenetic and molecular subtypes of AML.
Materials and methods
Patients
Bone marrow (BM) samples from 65 AML patients re-
ferred for treatment at our institution between August
1999 and November 2007 were studied; twenty-four new
patients and forty-one previously studied [17]. There
were no special criteria for the selection of patients
other than available RNA samples at diagnosis, and
informed consent for biological studies. Clinical,
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acteristics of the patients are summarized in Table 5.
According to the UK Medical Research Council (MRC)
cytogenetic features criteria [33], 15 patients had favor-
able cytogenetic features, 31 had an intermediate prog-
nosis, and 12 had bad prognostic features; seven patients
were missed for this classification. The study was
approved by our Institutional Review Board and all
patients gave their consent for blood samples to be fur-
ther processed.
Therapy
Fifty patients were treated with chemotherapy; 41 AML
non-M3 patients received one or two cycles of Idarubicin/
Cytarabine induction treatment and one consolidation
cycle with Cytarabine (1 g/m2), and later underwent high
dose chemotherapy and autologous stem cell transplant-
ation (15 cases) or allogeneic stem cell transplantationTable 5 Demographic and clinical characteristics of 65
acute myeloid leukemia (AML) patients
Characteristics Patients
Gender patients (male/female) 65 (37/28)
Age, median (range) 51 (16-76)
WBC count (X109/L), median (range) 13.4 (0.580-292)
Hemoglobin (g/dL), median (range) 9.6 (5.6-12.7)
Platelet count (X109/L), median (range) 68 (11-538)








De novo AML/Secondary AML 51/14




Blasts in peripheral blood (%), median (range) 32.5 (2-98)
Blasts in bone marrow (%), median (range) 79 (20-100)




Blast CD34+ (YES/NO) 33/31





Patient eligible/not eligible for treatment 50/15
24 were new patients and 41 were previously studied [17]. PS, Performance
Status. WBC, white blood cell. FAB indicates French American British
classification [19] and WHO indicates World Health Organization classification
[20]. MRC, cytogenetic classification of Medical Research Cancer [21].(seven cases). Nine AML M3 patients were treated
according to APL99 and APL 2005 PETHEMA protocols
[34]. Secondary AML was considered when there was pre-
vious chemotherapy treatment or myelodysplastic syn-
drome. Fifteen non-APL patients over 70 years and with
associated co-morbidities were not treated and were
excluded from the survival analysis.
GATA1, GATA2, EKLF and cMPL mRNA expression
GATA1, GATA2, EKLF and cMPL mRNA expression
was assessed in all cases as previously described [17]. To
assess the quality and quantity of the isolated RNA, as
well as the efficiency of cDNA synthesis, each sample
was normalized against the expression of beta-
glucuronidase (GUS). The construction of standard
curves for quantification of the transcription factors and
the internal control GUS, and calculation of GATA1,
GATA2, EKLF and cMPL copy number normalized to
GUS copy number, were performed as previously
reported [17]. Quantification was performed by calculat-
ing the ratios of the target gene in a standard curve rela-
tive to the control gene. All expression ratios are given
as 100x target gene/GUS.
Cytogenetics and mutational analysis of the FLT3, NPM1
and CEBPA genes
Karyotypes were analyzed after G-banding and described
according to the International System for Human Cyto-
genetic nomenclature [35]. Mutational analysis of FLT3-
ITD was assessed in 34 cases, as previously described
[36]. The presence of NPM1 gene mutations was
assessed in 44 cases, as previously described. The pres-
ence of CEBPA gene mutations was assessed in 33 cases,
as previously described [37].
Definition of clinical end points
Complete remission (CR) was defined as recovery of
morphologically normal BM and blood counts (i.e., neu-
trophils 1,500/μL and platelets 100,000/μL), and no cir-
culating leukemic blasts or evidence of extramedullary
involvement. EFS was defined as the interval from the
date of study until removal from the study because of
failure to achieve CR, relapse, or death as a result of any
cause (whichever occurred first). Patients alive without
relapse were censured, whereas those who died without
relapse were counted as a competing cause of failure.
Statistical methods
The following variables collected at diagnosis were
included in the database: gender, age (both as a continu-
ous variable and grouping patients over and under 55
years of age), Eastern Cooperative Oncology Group per-
formance status (ECOG PS), white blood cell (WBC)
count, platelet count, hemoglobin (Hb) level, percentage
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cells), percentage of erythroblast in BM (in three groups
0–5%/5– 15%/>15%), immunophenotypes, cytogenetics,
and World Health Organization (WHO) [38] and French
American British (FAB) [39] classifications.
Karyotype findings were grouped according to the Med-
ical Research Council (MRC) classification [33] into: (1)
favorable cytogenetic markers; (2) intermediate (no abnor-
malities, +8, 11q23, del [9q], +22, and other abnormalities
not included in the other groups); and (3) adverse cyto-
genetics (complex, - 7, abnormalities in 3q, del [5q] and
−5). Seven patient karyotypes were unavailable.
Analysis of GATA1, GATA2, EKLF, and c-MPL mRNA
expression and overexpression were done with FAB sub-
types AML and grouping: M2 against non-M2; M3
against non-M3 and M5 against non-M5 (these being
the great majority of cases studied). Expression was
defined as detection of a transcription factor versus its
absence. Overexpression was defined as expression
values over the median: Gata1/GUS> 0.057% for
GATA1; Gata2/GUS> 0.272% for GATA2; EKLF/GUS
> 0.177% for EKLF, and c-Mpl/GUS> 0.839% for
c-MPL.
Survival studies were carried out in the patients trea-
ted with chemotherapy. Overall survival (OS) was calcu-
lated from the first day of therapy to death, and Event
Free Survival (EFS) to no response, relapse, or death.
Kaplan-Meier life tables were constructed for survival
data and were compared by means of the log-rank test,
with a census of the surviving patients taken in July,
2007. Median follow-up was 19.4 months (range 0.5–
62.1 months). Results with a P value of less than 0.05
were considered significant.
A conditional logistic-regression model was used to
analyze associations between baseline characteristics and
GATA1, GATA2, EKLF, and cMPL mRNA expression,
or the NPM1, FLT3 and CEBPA mutations. A Cox
model was used to identify prognostic variables.
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Synopsis
Disturbance of mRNA expression of erythroid transcription factors, such as
EKLF, GATA1 or GATA2, has been shown in patients with acute myeloid
leukemia (AML), but no direct link to the mutations responsible for
leukemogenesis has been demonstrated. We studied the role of these
transcription factors in AML in the context of other prognostic molecular
markers, such as FLT3-ITD, NPM1 and CEBPA mutations.
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